NCT02446236View on ClinicalTrials.gov

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 18, 2015

Primary Completion Date

January 3, 2017

Study Completion Date

October 31, 2025

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Lenalidomide

Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21

DRUG

Ibrutinib

560 mg PO daily

DRUG

Rituximab

375 mg/m2 IV Day 1

Trial Locations (1)

07601

The Cancer Center at Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Hackensack Meridian Health

OTHER